RT Journal Article
SR Electronic
T1 A high content microscopy-based platform for detecting antibodies to the nucleocapsid, spike and membrane proteins of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.14.21264873
DO 10.1101/2021.10.14.21264873
A1 Williams, Daniel M.
A1 Hornsby, Hailey
A1 Shehata, Ola M.
A1 Brown, Rebecca
A1 Zafred, Domen
A1 Shun-Shion, Amber S.M.
A1 Hodder, Anthony J.
A1 Bliss, Deepa
A1 Metcalfe, Andrew
A1 Edgar, James R.
A1 Gordon, David E.
A1 Sayers, Jon R.
A1 Nicklin, Martin J.
A1 Collini, Paul J.
A1 Brown, Steve
A1 de Silva, Thushan I.
A1 Peden, Andrew A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.14.21264873.abstract
AB The strong humoral immune response produced against the SARS-CoV-2 nucleocapsid (N) and spike (S) proteins has underpinned serological testing but the prevalence of antibody responses to other SARS-CoV-2 proteins, which may be of use as further serological markers, is still unclear. Cell-based serological screening platforms can fulfil a crucial niche in the identification of antibodies which recognise more complex folded epitopes or those incorporating post-translation modifications which may be undetectable by other methods used to investigate the antigenicity of the SARS-CoV-2 proteome. Here, we employed automated high content immunofluorescence microscopy (AHCIM) to assess the viability of such an approach as a method capable of assaying humoral immune responses against full length SARS-CoV-2 proteins in their native cellular state. We first demonstrate that AHCIM provides high sensitivity and specificity in the detection of SARS-CoV-2 N and S IgG. Assessing the prevalence of antibody responses to the SARS-CoV-2 structural membrane protein (M), we further find that 85% of COVID-19 patients within our sample set developed detectable M IgG responses (M sensitivity 85%, N sensitivity 93%, combined N + M sensitivity 95%). The identification of M as a serological marker of high prevalence may be of value in detecting additional COVID-19 cases during the era of mass SARS-CoV-2 vaccinations, where serological screening for SARS CoV-2 infections in vaccinated individuals is dependent on detection of antibodies against N. These findings highlight the advantages of using cell-based systems as serological screening platforms and raise the possibility of using M as a widespread serological marker alongside N and S.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by BBSRC (BB/S009566/1; BB/J014443/1) Wellcome Trust and the Royal Society (216370/Z/19/Z). The Danson Foundation (DAN5819). Sheffield Teaching Hospitals NHS Foundation Trust and Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the University of Sheffield gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.